Key clinical point: Neurofilament light chain is the first blood biomarker for Parkinson’s disease progression.
Major finding: Neurofilament light chain in the cerebrospinal fluid can distinguish Parkinson’s disease from multiple system atrophy and progressive supranuclear palsy.
Study details: A retrospective analysis of 514 serum samples).
Disclosures: The study was funded by the Michael J. Fox Foundation for Parkinson’s Research. Dr. Vaou had no relevant financial disclosures.
Mollenhauer B et al. Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.